{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"239"}]}],"title":"Maximum QTcF Interval < 450 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"26"}]}],"title":"Maximum QTcF Interval 450 - 500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}]}],"title":"Maximum QTcF Interval > 500 msec"}],"denoms":[{"counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"270"}],"units":"Participants"}],"description":"A12-lead ECG was obtained at baseline (baseline=within 2 weeks prior to randomization) and once between Day 8 and 29. Additional ECGs were done at the Investigator's discretion. ECGs were read centrally. QT Interval corrected with Fridericia formula was measured in msec.","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant..","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study drug and had appropriate ECG data available were analyzed. Participants were analyzed based on the treatment they actually received, not what they were randomized to receive.","reportingStatus":"POSTED","timeFrame":"Baseline up to Year 2","title":"Number of Participants With Maximal QTcF Intervals up to Year 2 in Treated Participants","type":"SECONDARY","unitOfMeasure":"participants"}